Ignite Creation Date:
2024-05-05 @ 6:35 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00505453
Status:
COMPLETED
Last Update Posted:
2016-11-04
First Post:
2007-07-20
Brief Title:
A Phase III Open-Label Single-Dose Study to Evaluate the Safety and Immunogenicity of Fluviral Vaccine
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Phase III Open-Label Single-Dose Study to Evaluate the Safety and Immunogenicity of Fluviral Trivalent Split Virion Influenza Vaccine 2007 - 2008 Season in Adults Ranging in Age From 18 to 60 Years and 61 Years and Over
Status:
COMPLETED
Status Verified Date:
2016-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Vaccination is currently the most effective means of controlling influenza and preventing its complications and mortality in persons at risk
Once a year a meeting of WHO experts takes place leading to a recommendation on the influenza A and B strains that should be used for the production of vaccine for the coming influenza season
This study is designed to test the safetyreactogenicity and the immunogenicity of the Fluviral Trivalent Split Virion Influenza Vaccine containing the influenza strains recommended for the 2007-2008 season
Once a year a meeting of WHO experts takes place leading to a recommendation on the influenza A and B strains that should be used for the production of vaccine for the coming influenza season
This study is designed to test the safetyreactogenicity and the immunogenicity of the Fluviral Trivalent Split Virion Influenza Vaccine containing the influenza strains recommended for the 2007-2008 season
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None